Merck filings could expand heart division

Share this article:
Merck said Monday that it's readying two FDA submissions for drugs that could bolster its cardiovascular portfolio, the company's third-largest sales division.

The first will be for anti-clotting medication Vorapaxar. The submission is a bit of a retread – the company abandoned clinical trials just two years ago among patients with a history of stroke and acute coronary syndrome. This time Merck's approach is as a preventive measure among patients with a history of heart attack, but no history of stroke. The company said in a statement that it expects to file for this indication in the US and EU next year.

The second application is for cholesterol-lowering drug Tredaptive/MK-524-A, and is also on target for 2013 in the US and EU, the firm said. The extended-release niacin/laropiprant straddles a touchy category—an FDA study from 2011 found that niacin didn't do much in the battle to lower CV mortality. Merck shelved its niacin/simvastatin combination known as MK-0524B earlier this month.

Approvals of the drugs would expand a segment of Merck's portfolio responsible for $2.4 billion in sales last year, good enough for third among the contributors to its sales tallies, behind respiratory's $5.5 billion in sales and the diabetes division's $3.3 billion in revenues.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.